5-HTP

Anter

• E kūpono paha no ...
• ʻAʻole kūpono paha no ...
• ʻAʻole lawa nā hōʻike e hōʻike i ka pono no ...
• Nā mālama a me nā ʻōlelo aʻoaʻo kūikawā:

5-HTP (5-hydroxytr Egyptophan) kahi huahana kemika o ka poloka hale kūkulu ʻo L-tryptophan. Hoʻopuka ʻia ia mea kālepa mai nā ʻanoʻano o kahi mea kanu ʻApelika i kapa ʻia ʻo Griffonia simplicifolia.

Hoʻohana ʻia ʻo 5-HTP no nā maʻi hiamoe e like me ka hiamoe, kaumaha, hopohopo, a me nā ʻano ʻē aʻe he nui, akā ʻaʻohe hōʻike ʻepekema maikaʻi e kākoʻo i ka hapa nui o kēia mau hoʻohana.

Nā Laʻau Laʻau Kūlohelohe Kūlohelohe nā helu kūpono e pili ana i nā hōʻike ʻepekema e like me ka pālākiō e hiki mai ana: Ka maikaʻi, ka hopena maikaʻi, ka hopena maikaʻi, ka hopena maikaʻi ʻole, ka maikaʻi ʻole, ka maikaʻi ʻole, a me ka lawa ʻole o nā hōʻike i ka helu.

Nā helu kūpono no 5-HTP penei:

E kūpono paha no ...

• Kaumaha. Lawe i ka 5-HTP e ka waha e hoʻomaikaʻi i nā ʻōuli o ke kaumaha i kekahi poʻe. Hōʻike kekahi mau noiʻi noiʻi e lawe ana i ka 5-HTP e ka waha he mea maikaʻi paha e like me kekahi mau lāʻau antidepressant kuhikuhi no ka hoʻomaikaʻi ʻana i nā hōʻailona kaumaha. I ka hapanui o nā noi ʻana, 150-800 mg i kēlā me kēia lā o 5-HTP i lawe ʻia. I kekahi mau hihia, ua hoʻohana ʻia nā lāʻau kiʻekiʻe.

ʻAʻole kūpono paha no ...

• Down syndrome. Hōʻike kekahi mau noiʻi e hāʻawi ana i ka 5-HTP i nā pēpē me Down Syndrome e hoʻomaikaʻi paha i ka mākala a me ka hana. Hōʻike nā noiʻi ʻē aʻe ʻaʻole ia e hoʻomaikaʻi i ka mākala a i ʻole ke hoʻomohala ke lawe ʻia mai ka wā kamaliʻi a hiki i ka 3-4 mau makahiki. Hōʻike pū kekahi nā noiʻi e lawe ana i ka 5-HTP me nā lāʻau lapaʻau maʻamau e hoʻomaikaʻi i ka hoʻomohala ʻana, nā mākau pilikanaka, a i ʻole nā ​​mākau ʻōlelo.

ʻAʻole lawa nā hōʻike e hōʻike i ka pono no ...

• Ke ʻano o ka hopohopo i kaha ʻia e nā manaʻo hou a me nā ʻano hana hou (obsessive-compulsive maʻi a i ʻole OCD). Hōʻike ka noiʻi mua i ka lawe ʻana i 5-HTP me ka lāʻau antidepressant fluoxetine (Prozac) no 12 mau pule e hoʻomaikaʻi ai i kekahi mau ʻōuli o OCD.
• Hoʻohana maʻi ʻalekohola. Hōʻike ka noiʻi mua i ka lawe ʻana i 5-HTP me D-phenylalanine a me L-glutamine no 40 mau lā e hiki ai ke hōʻemi i nā hōʻailona haʻalele ʻana i ka waiʻona. Eia naʻe, ʻo ka lawe ʻana i 5-HTP me carbidopa i kēlā me kēia lā no hoʻokahi makahiki ʻaʻole ia e kōkua i ka poʻe e hōʻoki i ka inu. ʻAʻole maopopo ka hopena o 5-HTP wale no ka waiʻona.
• Maʻi Alzheimer. Hōʻike ka noiʻi mua i ka lawe ʻana i 5-HTP e ka waha ʻaʻole ia e kōkua i nā hōʻailona o ka maʻi Alzheimer.
• Hopohopo. ʻAʻole maopopo nā hōʻike e pili ana i nā hopena o 5-HTP no ka hopohopo. Hōʻike ka noiʻi mua i ka lawe ʻana i 25-150 mg o 5-HTP e ka waha i kēlā me kēia lā me ka carbidopa e hōʻemi ana i nā ʻōuli o ka hopohopo i ka poʻe me nā maʻi hopohopo. Eia nō naʻe, hōʻike kahi noiʻi ʻē aʻe i ka lawe ʻana i nā kaola ʻoi loa o 5-HTP, 225 mg i kēlā me kēia lā a ʻoi paha, e like me ka mea e hoʻonui ai i ka hopohopo. Eia kekahi, ʻo ka lawe ʻana i 60 mg o 5-HTP i kēlā me kēia lā ma o ka aa koko ʻaʻole ia e hōʻemi i ka hopohopo i ka poʻe me nā maʻi panic.
• Hoʻopilikia ka lolo e pili ana i ka neʻe ʻana o ka mākala (cerebellar ataxia). ʻAʻole maopopo nā hōʻike e pili ana i ka hoʻohana ʻana o 5-HTP no ka ata ceria cerebellar. Hōʻike nā hōʻike mua i ka lawe ʻana i 5 mg / kg o 5-HTP i kēlā me kēia lā no 4 mau mahina e hiki ai ke hōʻemi i ka hana ʻōnaehana nerve. Eia nō naʻe, hōʻike ʻia kahi noiʻi ʻē aʻe i ka lawe ʻana i ka 5-HTP i kēlā me kēia lā a i hoʻokahi makahiki ʻaʻole e hoʻomaikaʻi i nā ʻōuli o cerebellar ataxia.
• ʻO Fibromyalgia. Hōʻike ka noiʻi mua i ka lawe ʻana i 100 mg o 5-HTP e ka waha ʻekolu manawa i kēlā me kēia lā no 30-90 mau lā e hoʻomaikaʻi ai i ka ʻeha, palupalu, hiamoe, hopohopo, luhi, a me ka ʻoʻoleʻa kakahiaka i ka poʻe me fibromyalgia.
• Nā ʻōuli o ka menopause. Hōʻike ka ʻimi noiʻi mua i ka lawe ʻana i 150 mg o 5-HTP i kēlā me kēia lā no 4 mau pule ʻaʻole e hoʻemi i nā wela wela i nā wahine postmenopausal.
• ʻO Migraine. ʻAʻole maopopo nā hōʻike e pili ana i nā hopena o 5-HTP no ka pale a me ka mālama ʻana i ka migraines i nā mākua. Hōʻike kekahi mau noiʻi i ka lawe ʻana i 5-HTP i kēlā me kēia lā ʻaʻole e hoʻemi i ka migraines, ʻoiai e hōʻike ana nā noiʻi ʻē aʻe he maikaʻi paha e like me nā lāʻau lapaʻau. ʻAʻole like ka 5-HTP i mea e hōʻemi ai i ka migraines i nā keiki.
• Ka momona. Hōʻike ka noiʻi mua i ka lawe ʻana i 5-HTP i mea e hōʻemi ai i ka makemake, ka ʻai ʻana o ka caloric, a me ke kaupaona i nā poʻe momona. Hōʻike nā noiʻi ʻē aʻe i ka hoʻohana ʻana i kahi ʻūlū waha kikoʻī nona ka 5-HTP a me nā mea unuhi ʻē aʻe (5-HTP-Nat Exts, Medestea Biotech S.p.a., Torino, ʻItalia) no 4 mau pule e hoʻonui ai i ka pohō kaumaha ma kahi o 41% i nā wahine postmenopausal nui.
• Ka haʻalele ʻana mai heroin, morphine, a me nā lāʻau opioid ʻē aʻe. Hōʻike ka noiʻi mua i ka lawe ʻana i 200 mg o 5-HTP i kēlā me kēia lā no 6 mau lā me ka tyrosine, phosphatidylcholine, a me L-glutamine, e hōʻemi paha i ka hiamoe ʻole a me nā hōʻailona haʻalele i ka loaʻa hou ʻana o nā addict heroin.
• Maʻi ʻo Parkinson. Hōʻike ka noiʻi mua i ka lawe ʻana i ka 100-150 mg o 5-HTP e ka waha i kēlā me kēia lā me nā lāʻau maʻamau e hōʻemi i ka haʻalulu, akā hoʻomau mau kēia mau pōmaikaʻi a hiki i 5 mau mahina. Hōʻike nā noiʻi ʻē aʻe i ka lawe ʻana i 50 mg o 5-HTP i kēlā me kēia lā e hōʻemi paha i nā ʻōuli o ka neʻe ʻana mai ka lāʻau levodopa, a me nā ʻōuli o ke kaumaha, i ka poʻe me ka maʻi Parkinson. Akā ʻo ka lawe ʻana i nā lāʻau nui o 5-HTP, 275-1500 mg i kēlā me kēia lā, me ka carbidopa e hoʻomāhuahua ai i kekahi mau ʻōuli.
• ʻEha poʻo hina. Hōʻike ka noiʻi mua i ka lawe ʻana i 100 mg o 5-HTP ʻekolu mau manawa i kēlā me kēia lā no 8 mau pule ʻaʻole e hoʻēmi i ka ʻeha a me ka lōʻihi o nā headache tension.
• Ka maʻi deficit-hyperactivity maʻi (ADHD).
• ʻO Insomnia.
• ʻO ka maʻi maʻi maʻi ʻole Premenstrual (PMDD).
• Premenstrual Syndrome (PMS).
• ʻO Ramsey-Hunt maʻi.
• Nā kūlana ʻē aʻe.

Pono nā hōʻike hou aʻe e helu i ka pono o 5-HTP no kēia mau hoʻohana.

Hana ka 5-HTP i ka lolo a me ka ʻōnaehana waena e ka hoʻonui ʻana i ka hana o ka serotonin kemika. Hiki i ka Serotonin ke hoʻopili i ka hiamoe, ka makemake, ka mahana, ka moekolohe a me ka ʻeha. Ma muli o ka hoʻonui ʻana o 5-HTP i ka synthesist o serotonin, hoʻohana ʻia ia no nā maʻi he nui kahi i manaʻo ʻia he koʻikoʻi ka serotonin e like me ke kaumaha, ka hiamoe, ka momona, a me nā kumu ʻē aʻe he nui.

Ke lawe ʻia e ka waha: 5-HTP ʻo ia SAFE MAU PONO ke lawe pono ʻana ma ka waha. Hoʻohana palekana ʻia ia i nā kaona a i ka 400 mg i kēlā me kēia lā a i hoʻokahi makahiki. Akā ʻo kekahi poʻe i lawe i 5-HTP ua hoʻomohala i kahi kūlana i kapa ʻia ʻo eosinophilia-myalgia syndrome (EMS). He kūlana koʻikoʻi ʻo EMS e pili ana i ka palupalu o ka nāhelehele (myalgia) a me nā mea kūpono ʻole o ke koko (eosinophilia). Manaʻo kekahi poʻe ua hoʻokumu ʻia ʻo EMS e kahi mea hana kuʻuna ʻole a haumia paha i kekahi huahana 5-HTP. Akā ʻaʻole lawa nā hōʻike ʻepekema e ʻike inā e hoʻokumu ʻia ʻo EMS e 5-HTP, kahi mea haumia, a i ʻole kekahi mea ʻē aʻe. A hiki i ka ʻike hou aku, 5-HTP e hoʻohana akahele.

ʻO nā hopena ʻē aʻe o 5-HTP e komo pū me ka puʻuwai puʻuwai, ʻeha o ka ʻōpū, nausea, ka luaʻi, ka palahē, ka hiamoe, nā pilikia moekolohe, a me nā pilikia o ka mākala.

5-HTP ʻo POSSIBLY UNSAFE ke lawe ʻia e ka waha i nā kaha nui. Hoʻohui ʻia nā hana mai 6-10 mau lā i nā pilikia o ka ʻōpū koʻikoʻi a me nā spasms muscle.

Nā mālama a me nā ʻōlelo aʻoaʻo kūikawā:

Hāpai a me ka hānai umauma: ʻAʻole lawa ka ʻike pono e ʻike inā palekana ʻo 5-HTP e hoʻohana i ka wā hāpai a hānai umauma paha. Noho ma ka ʻaoʻao palekana a pale i ka hoʻohana.

Nā keiki: 5-HTP ʻo ia SAFE MAU PONO ke lawe ʻia e ka waha kūpono. Hoʻohana palekana ʻia nā hana a i 5 mg / kg i kēlā me kēia lā a hiki i 3 mau makahiki i nā pēpē a me nā keiki a hiki i ka 12-makahiki. E like me ka poʻe mākua, aia kekahi hopohopo e pili ana i ka hiki no ka eosinophilia-myalgia syndrome (EMS) i loko o nā keiki, kahi ʻano koʻikoʻi e pili ana i ka palupalu o nā mākala (myalgia) a me nā mea ʻino o ke koko (eosinophilia).

ʻOki kino: 5-HTP hiki ke hoʻopili i kahi kemika lolo i kapa ʻia serotonin. ʻO kekahi mau lāʻau i lawelawe ʻia i ka wā o ke ʻoki ʻana hiki ke hoʻololi i ka serotonin. Lawe i ka 5-HTP ma mua o ke kahakaha ʻana i kumu nui ai ka serotonin i ka lolo a hiki i nā hopena hopena koʻikoʻi me nā pilikia puʻuwai, haʻalulu, a me ka hopohopo. E haʻi i nā mea maʻi e hōʻoki i ka lawe ʻana i 5-HTP ma ka liʻiliʻi he 2 mau pule ma mua o ke kaha ʻana.

Mekia

Mai lawe i kēia hui ʻana.

Nā lāʻau no ke kaumaha (MAOI)

Hoʻonui ka 5-HTP i kahi kemika i ka lolo i kapa ʻia serotonin. Hoʻonui kekahi mau lāʻau i hoʻohana ʻia no ke kaumaha e hoʻonui ai i ka serotonin. Lawe iā 5-HTP me kēia mau lāʻau i hoʻohana ʻia no ke kaumaha e hoʻonui ai i ka serotonin. Hiki i kēia ke kumu i nā hopena ʻino e pili ana i ka ʻeha poʻo, nā pilikia puʻuwai, haʻalulu, huikau, a me nā hopohopo

ʻO kekahi o kēia mau lāʻau i hoʻohana ʻia no ke kaumaha me phenelzine (Nardil), tranylcypromine (Parnate), a me nā mea ʻē aʻe.

Kānāwai

E akahele me kēia hui ʻana.

Carbidopa (Lodosyn)

Hiki i ka 5-HTP ke hoʻopili i ka lolo. Hiki i ka Carbidopa (Lodosyn) ke hoʻopili i ka lolo. Lawe i ka 5-HTP me ka carbidopa hiki ke hoʻonui i ka hopena o nā hopena ʻē aʻe e like me ka ʻōlelo wikiwiki, ka hopohopo, ka huhū, a me nā mea ʻē aʻe.

Nā lāʻau lapaʻau hōʻoluʻolu (depressants CNS)

5-HTP paha ke kumu o ka hiamoe a me ka hiamoe. ʻO nā lāʻau i kumu e hiamoe ai i kapa ʻia ʻo nā mea hōʻohi. Lawe i ka 5-HTP me nā lāʻau hoʻohiamoe e hoʻonāukiuki paha.

ʻO kekahi mau lāʻau hoʻohiehie e komo pū me clonazepam (Klonopin), lorazepam (Ativan), phenobarbital (Donnatal), zolpidem (Ambien), a me nā mea ʻē aʻe.

Nā lāʻau Serotonergic

5-HTP hiki ke hoʻonui i kahi kemika i ka lolo i kapa ʻia serotonin. Hoʻonui pū kekahi mau lāʻau i ka serotonin. Lawe i ka 5-HTP me kēia mau lāʻau e hoʻonui ai i ka serotonin. Hiki i kēia ke kumu i nā hopena ʻino e pili ana i ka ʻeha poʻo, nā pilikia puʻuwai, haʻalulu, huikau, a me nā hopohopo.

ʻO kekahi o kēia mau lāʻau e pili pū ana me fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Tofranil), sumatriptan (Imitrex), zolmitriptan (Zomig), rizatran methadone (Dolophine), tramadol (Ultram), a me nā mea ʻē aʻe he nui.

Nā mea kanu a me nā mea hoʻopihapiha me nā mea hoʻohiamoe

Hiki i ka 5-HTP ke hana i ka hiamoe a hiamoe paha. Ke hoʻohana nei ia me nā mea kanu a me nā mea hoʻopili ʻē aʻe i like ka hopena e hopena i ka hiamoe nui. ʻO kekahi o kēia mau mea kanu a me nā mea hoʻopihapiha me ka calamus, California poppy, catnip, hops, Jamaican dogwood, kava, St. John's wort, skullcap, valerian, yerba mansa, a me nā mea ʻē aʻe.

Nā mea kanu a me nā mea hoʻopihapiha me nā waiwai serotonergic

Hoʻonui ka 5-HTP i kahi kemikolo lolo i kapa ʻia serotonin. Lawe i ka 5-HTP me nā mea kanu a me nā mea hoʻopili ʻē aʻe e hoʻonui i ka serotonin e alakaʻi i ka serotonin he nui a hana i nā hopena me nā pilikia puʻuwai, haʻalulu a me ka hopohopo. ʻO nā mea kanu a me nā mea hoʻopihapiha ʻē aʻe e hoʻonui ai i ke kiʻekiʻe o ka serotonin e komo pū ana me ka pēpē pēpē Hawaiʻi, L-tryptophan, S-adenosylmethionine (SAMe), a me ko St.

ʻAʻole ʻike ʻia nā launa me nā meaʻai.

Ua aʻo ʻia nā mahele aʻe i ka noiʻi ʻepekema: NA MAKAHIKI

E ka waha:

• No ke kaumaha: ʻO ka mea maʻamau, lawe ʻia ka 150-800 mg i kēlā me kēia lā no 2-6 mau pule. Hoʻokaʻawale ʻia kēia mau kaha a lawelawe ʻia e like me 50 mg i 100 mg ʻekolu mau manawa i ka lā. I kekahi manawa hoʻomaka ka mahele haʻahaʻa a hoʻonui mau i kēlā me kēia 1-2 mau pule a hiki i ka hōʻili ʻia ʻana o kahi lāʻau. ʻO ka liʻiliʻi, hoʻohana ʻia nā lāʻau kiʻekiʻe. I hoʻokahi aʻo, hoʻonui mau ʻia ka lāʻau i 3 gram i kēlā me kēia lā.

2-Amino-3- (5-Hydroxy-1H-Indol-3-yl) ʻO Propanoic Acid, 5 Hydroxy-Tryptophan, 5 Hydroxy-Tryptophane, 5-Hydroxytr Egyptophan, 5-Hydroxytr Egyptophane, 5-Hydroxy L-Tryptophan, 5-Hydroxy L-Tryptophane, 5-Hydroxy Tryptophan, 5-L-Hydroxytr Egyptophan, L-5 HTP, L-5-Hydroxytr Egyptophan, L-5-Hydroxytr Egyptophane, Oxitriptan.

E aʻo hou aʻe ai pehea i kākau ʻia ai kēia ʻatikala, e ʻoluʻolu e ʻike i ka Nā Laʻau Laʻau Kūlohelohe Kūlohelohe ʻano hana.

1. Meloni M, Puligheddu M, Sanna F, et al. Ka maikaʻi a me ka palekana o 5-Hydroxytr Egyptophan ma luna o ka levodopa i hoʻokomo ʻia i nā pilikia ma ka maʻi ʻo Parkinson: kahi ʻike mua. ʻO J Neurol Sci. 2020; 415: 116869. Nānā kiʻi ʻole.
2. Yousefzadeh F, Sahebolzamani E, Sadri A, et al. 5-Hydroxytr Egyptophan ma ke ʻano he adjuvant therapy i ka hoʻomaʻamaʻa ʻana i ka maʻi maʻamau a koʻikoʻi paha: kahi hoʻokolokolo kaulua makapō makapō me ka kaʻi o ka placebo. Int Clin Psychopharmacol. 2020; 35: 254-262. Nānā kiʻi ʻole.
3. Javelle F, Lampit A, Bloch W, Häussermann P, Johnson SL, Zimmer P. Nā hopena o 5-hydroxytr Egyptophan ma nā ʻano like ʻole o ke kaumaha: kahi loiloi ʻōnaehana a me nā meta-analysis. Nutr Rev 2020; 78: 77-88. Nānā kiʻi ʻole.
4. Meloni M, Puligheddu M, Carta M, Cannas A, Figorilli M, Defazio G. Ka maikaʻi a me ka palekana o 5-hydroxytr Egyptophan ma ke kaumaha a me ka apathy i ka maʻi o Parkinson: kahi ʻike mua. Eur J Neurol 2020; 27: 779-786. Nānā kiʻi ʻole.
5. Israeliana N, Del Colle A, Li Z, et al. Nā hopena o Serotonin a me Slow-Release 5-Hydroxytr Egyptophan ma Gastrointestinal Motility i kahi Kiʻina Kiʻi o ke kaumaha. Gastroenterology. 2019; 157: 507-521.e4. Nānā kiʻi ʻole.
6. ʻO Michelson D, ʻAoʻao SW, Casey R, et al. ʻO kahi maʻi eosinophilia-myaligia e pili ana i ka maʻi e pili ana i ka hōʻike ʻana i ka l-5-hydroxytr Egyptophan. ʻO J Rheumatol 1994; 21: 2261-5. Nānā kiʻi ʻole.
7. Lemaire PA, Adosraku RK. ʻO kahi hana HPLC no ka hoʻāʻo pololei o ka prerororor precursor, 5-hydroxytrophan, i nā hua o Griffonia simplicifolia. Phytochem Anal 2002; 13: 333-7.
8. ʻO Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S. Ka pilina ma waena o ka lawe ʻia ʻana o 5-hydroxytr Egyptophan mai kahi papaʻai i hoʻohui ʻia, ma o Griffonia simplicifolia extract, a me ka hopena o ka māʻona i nā wahine ʻoi ke kaumaha ma hope o ka hoʻoponopono ʻana o ka waha. Eʻai i ka hoʻokaumaha kaumaha 2012; 17: e22-8. Nānā kiʻi ʻole.
9. Pardo JV. Mania e pili ana i ka hoʻohui o ka hydroxytr Egyptophan i ka monoamine oxidase inhibitor. ʻO Gen Hosp Psychiatry 2012; 34: 102.e13-4.
10. Chen D, Liu Y, He W, Wang H, Wang Z. Neurotransmitter-precursor-supplement interven for detoxified heroin addicts. ʻO J Huazhong Univ Sci Technolog Med Med 2012; 32: 422-7.
11. ʻO Gendle MH, Young EL, Romano AC. Nā hopena o ka 5-hydroxytr Egyptophan waha ma ka hana hoʻolālā maʻamau: ʻike i nā pilina dopamine / serotonin hiki i ka forebrain. Hum Psychopharmacol 2013; 28: 270-3.
12. ʻO ka hālāwai o ke Kōmike aʻoaʻo aʻoaʻo aʻoaʻo ʻo US Food and Drug Administration June 17-18, 2015. Loaʻa ma: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycomm Komiti/ucm455276.pdf (kiʻi ʻia 8/21/15).
13. ʻO ka US Food and Drug Administration. Nā inoa a me nā ʻae a nā keiki makua ʻole. Loaʻa ma: www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm (kiʻi ʻia 8/20/2015).
14. ʻO Das YT, Bagchi M, Bagchi D, Preuss HG. Ka palekana o 5-hydroxy-L-tryptophan. ʻO Toxicol Lett 2004; 150: 111-22. Nānā kiʻi ʻole.
15. Weise P, Koch R, Shaw KN, Rosenfeld MJ. ʻO ka hoʻohana ʻana o 5-HTP i ka mālama ʻana i ka Down Syndrome. Nā Pediatrics 1974; 54165-8. Nānā kiʻi ʻole.
16. ʻO Bazelon M, Paine RS, Cowie VA, et al. ʻO ka hoʻohuli hou ʻana o ka hiponia i nā pēpē me Down's syndrome e ka hoʻomalu ʻana o 5-hydroxytr Egyptophan. Lancet 1967; 1: 1130-3. Nānā kiʻi ʻole.
17. Sano I. ʻO ka hoʻōla o ke kaumaha me L-5-hydroxytr Egyptophan (L-5-HTP). ʻO Psychiatria et Neurologia Japonicas 1972; 74: 584.
18. Klein P, Lees A, a me Stern G. Nā hopena o ka 5-hydroxytr Egyptophan mau i ka parkinsonian instability o ka hele a me ke kaulike a me nā maʻi neurological ʻē aʻe. Adv Neurol 1986; 45: 603-604.
19. VanPraag, H. M. a me Korf, J. 5-Hydroxytr Egyptophan ma ke ʻano he antidepressant: Ka wānana waiwai o ka hoʻāʻo probenecid. Psychopharmacol.Bull. 1972; 8: 34-35.
20. ʻO Sicuteri F. 5-hydroxytr Egyptophan i ka prophylaxis o ka migraine. Nā kamaʻilio noiʻi noiʻi lāʻau lapaʻau 1972; 4: 213-218.
21. Rosano Burgio, F., Borgatti, R., Scarabello, E., a me Lanzi, G. Headache i nā keiki a me nā ʻōpio. Nā hana o ka International International Symposium ma Headache ma nā keiki a me nā Adolecents. 1989; 339-47.
22. Mathew NT. 5-hydroxytr Egyptophan i ka prophylaxis o migraine: kahi hoʻopaʻa makapō makapō. Headache 1978; 18: 111.
23. ʻO De Benedittis G, ʻo Massei R. 5-HT i mua o ka migraine prophylaxis: kahi papa pālua makapō makapō me L-5-hydroxytr Egyptophan. ʻO Clin J Pain 1986; 2: 123-129.
24. ʻO Wyatt, R. J., Vaughan, T., Kaplan, J., Galanter, M., a me Green, R. 5-Hydroxytr Egyptophan a me schizophrenia mau. I: Barchas J a me Usdin E. Serotonin a me ke ʻano. Nu Ioka: Hale Paʻi ʻĀpelika; 1973.
25. ʻO Brodie HKH, Sack R, a me Siever L. Ke aʻo maʻi ʻana o L-5-hydroxytr Egyptophan i ke kaumaha. I: Barchas J a me Usdin E. Serotonin a me ka lawena. Nu Ioka: Hale Paʻi Kula; 1973.
26. ʻO Auffret, M., Comte, H., a me Bene, J. Eosinophilia-myalgia maʻi i hoʻokomo ʻia e L-5 hydroxytr Egyptophane: ʻekolu paha mau hihia. Fund Clinac Pharmacol 2013; Mea hoʻolako 1: poster P2-204.
27. Cangiano C, Laviano A, Del Ben M, et al. Nā hopena o ka 5-hydroxy-tryptophan waha ma ka lawe ʻana i ka ikehu a me ke koho macronutrient i nā maʻi diabetic non-insulin hilinaʻi. Int J Obes Relat Metab Disord 1998; 22: 648-54. Nānā kiʻi ʻole.
28. Ju, C. Y. a me Tsai, C. T. Serotonergic ʻano hana i komo i ka suppression o ka hānai ʻana e 5-HTP i nāʻiole. Chin J Physiol 1995; 38: 235-240. Nānā kiʻi ʻole.
29. Pranzatelli, M. R., Tate, E., Galvan, I., a me Wheeler, A. He hoʻokolokolo hoʻokolokolo ʻia o 5-hydroxy-L-tryptophan no ka ataxia i ka myoclonus epilepsy holomua. ʻO Clin Neurol.Neurosurg. 1996; 98: 161-164. Nānā kiʻi ʻole.
30. Frith, C. D., Johnston, E. C., Joseph, M. H., Powell, R. J., a me Watts, R. W. Hoʻokolokolo ʻelua makapō makapō o 5-hydroxytr Egyptophan i kahi hihia o Lesch- Nyhan syndrome. ʻO J Neurol Neurosurg. Psychiatry 1976; 39: 656-662. Nānā kiʻi ʻole.
31. ʻO Bastard, J., Truelle, J. L., a me Emile, J. [Ka hopena o 5 hydroxy-tryptophan i ka maʻi ʻo Parkinson]. ʻO Nouv Presse Med 9-11-1976; 5: 1836-1837. Nānā kiʻi ʻole.
32. Trouillas P, Serratrice G, Laplane D, et al. Keʻano Levorotatory o 5-hydroxytr Egyptophan ma Friedreich's ataxia. Nā hopena o kahi noiʻi noiʻi lāʻau lāʻau makapō makapō-makapō. Arch Neurol 1995; 52: 456-60. Nānā kiʻi ʻole.
33. Wessel K, Hermsdörfer J, Deger K, et al. Ke aʻo crossover makapō makapō me ke ʻano levorotatory o hydroxytr Egyptophan i nā mea maʻi me nā maʻi cerebellar degenerative. Arch Neurol 1995; 52: 451-5. Nānā kiʻi ʻole.
34. Alino, J. J., Gutierrez, J. L., a me Iglesias, M. L. 5-Hydroxytr Egyptophan (5-HTP) a me kahi MAOI (nialamide) i ka mālama ʻana i nā kaumaha. ʻO kahi hoʻopaʻa ʻana i hoʻomalu ʻia me ka makapō makapō. Int Pharmacopsychiatry 1976; 11: 8-15. Nānā kiʻi ʻole.
35. Pranzatelli, M. R., Tate, E., Huang, Y., Haas, R. H., Bodensteiner, J., Ashwal, S., a me Franz, D. Neuropharmacology o ka myoclonus epilepsy holomua: pane i 5- hydroxy-L-tryptophan. Epilepsia 1995; 36: 783-791. Nānā kiʻi ʻole.
36. Thomson, J., Rankin, H., Ashcroft, GW, Yates, CM, McQueen, JK, a me Cummings, SW Ka mālama ʻana i ke kaumaha i ka hana maʻamau: kahi hoʻohālikelike o L-tryptophan, amitriptyline, a me kahi hui o L-tryptophan a me amitriptyline me ka placebo. Psychol Med 1982; 12: 741-751. Nānā kiʻi ʻole.
37. Trouillas, P., Garde, A., Robert, JM, Renaud, B., Adeleine, P., Bard, J., a me Brudon, F. [Ka hoʻi ʻana o ka maʻi cerebellar ma lalo o ka manawa lōʻihi o 5-HTP a i ʻole ka hoʻohui o 5-HTP a me benserazide. 26 mau helu i helu ʻia a mālama ʻia me ka hoʻohana ʻana i nā ʻano kamepiula]. Rev Neurol. (Paris) 1982; 138: 415-435. Nānā kiʻi ʻole.
38. ʻO Thal, L. J., Sharpless, N. S., Wolfson, L., a me Katzman, R. Hoʻomaʻamaʻa ʻana i ka myoclonus me L-5-hydroxytr Egyptophan a me carbidopa. Ann Neurol 1980; 7: 570-576. Nānā kiʻi ʻole.
39. van Hiele LJ. l-5-Hydroxytr Egyptophan i ke kaumaha: ʻo ka therapist substitusi mua loa i ka psychiatry? ʻO ka mālama ʻana i nā mea maʻi he 99 i waho me nā ʻehaʻeha kūpaʻa. Neuropsychobiology 1980; 6: 230-40. Nānā kiʻi ʻole.
40. Magnussen, I.a me Nielsen-Kudsk, F. Bioavailability a me nā pharmacokinetics e pili ana i ke kanaka o L-5-hydroxytr Egyptophan i lawelawe waha ʻia i ka mokuʻāina paʻa. Acta Pharmacol Toxicol. (Copenh) 1980; 46: 257-262. Nānā kiʻi ʻole.
41. Trouillas, P., Garde, A., Robert, J. M., a me Adeleine, P. [Ka hoʻi ʻana o ke kanaka cerebellar ataxia ma lalo o ka manawa lōʻihi o 5-hydroxytr Egyptophan]. C.R.Seances Acad Sci III 1-5-1981; 292: 119-122. Nānā kiʻi ʻole.
42. ʻO Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-hydroxytr Egyptophan a me pyridoxine. ʻO ko lākou hopena i nā keiki ʻōpio me Down's Syndrome. ʻO Am J Dis Child 1980; 134: 838-44. Nānā kiʻi ʻole.
43. Longo G, Rudoi I, Iannuccelli M, Strinati R, Panizon F. [Hoʻomaʻamaʻa i ka maʻi headache nui i ka makahiki ulu me L-5-HTP (keʻa i ka hoʻopaʻa makapō makapō me ka placebo) Pediatr Med Chir 1984; 6: 241-5. Nānā kiʻi ʻole.
44. ʻO Bono, G., Micieli, G., Sances, G., Calvani, M., a me Nappi, G. L-5HTP i mālama ʻia i nā poʻo hina mua: kahi hoʻāʻo e hōʻike i ka ʻike maʻi o nā mea maʻi pane. Cephalalgia 1984; 4: 159-165. Nānā kiʻi ʻole.
45. ʻO Quadbeck, H., Lehmann, E., a me Tegeler, J. Hoʻohālikelike o ka hana antidepressant o ka tryptophan, tryptophan / 5- hydroxytr Egyptophan hoʻohui a me ka nomifensine. Neuropsychobiology 1984; 11: 111-115. Nānā kiʻi ʻole.
46. van Praag, H. M. I ka ʻimi ʻana i ke ʻano o ka hana o nā antidepressants: 5-HTP / tyrosine mixtures i ke kaumaha. ʻO Adv Biochem Psychopharmacol. 1984; 39: 301-314. Nānā kiʻi ʻole.
47. ʻO Trouillas P. Ka hoʻi ʻana o ka maʻi cerebellar me ka hoʻoponopono lōʻihi o 5-HTP a i ʻole ka hui pū ʻana o 5-HTP-benserazide: 21 mau hihia me nā ʻōuli helu i hana ʻia e ka kamepiula. Ital J Neurol Sci 1984; 5: 253-266. Nānā kiʻi ʻole.
48. van Praag, H. M. a me de Haan, S. Chemoprophylaxis o nā kaumaha. ʻO kahi hoʻāʻo e hoʻohālikelike i ka lithium me 5- hydroxytr Egyptophan. ʻO Acta Psychiatr. Pūʻali Kūʻai 1981; 290: 191-201. Nānā kiʻi ʻole.
49. van Praag, H. a me de Hann, S. Pōʻino kaumaha a me 5-hydroxytr Egyptophan prophylaxis. ʻO Psychiatry Res. 1980; 3: 75-83. Nānā kiʻi ʻole.
50. Soulairac, A. [Ka hana hypnotic o mecloqualone. Hoʻohālikelike me nā hopena placebo a me secobarbital]. Presse Med 4-10-1971; 79: 817-818. Nānā kiʻi ʻole.
51. Chase, T. N., Ng, L. K., and Watanabe, A. M. Parkinson's disease. Hoʻololi e 5-hydroxytr Egyptophan. ʻO Neurology 1972; 22: 479-484. Nānā kiʻi ʻole.
52. ʻO Wyatt, R. J., Vaughan, T., Galanter, M., Kaplan, J., a me Green, R. Hoʻololi i ka lawena o nā mea maʻi schizophrenic mau i hāʻawi ʻia iā L-5- hydroxytr Egyptophan. ʻEpekema 9-22-1972; 177: 1124-1126. Nānā kiʻi ʻole.
53. van Praag HM, Korf J, Dols LC, Schut T. He pailota hoʻopaʻa haʻawina o ka wānana waiwai o ka probenecid hōʻike i ka noi ʻana o 5-hydroxytr Egyptophan ma ke ʻano he antidepressant. ʻO Psychopharmacologia 1972; 25: 14-21. Nānā kiʻi ʻole.
54. Zarcone, V., Kales, A., Scharf, M., Tan, T. L., Simmons, J. Q., a me Dement, W. C. Hoʻokomo ʻia ka waha waha o 5-hydroxytr Egyptophan. ʻO ka hopena ma ka lawena a me nā hana hiamoe i nā keiki schizophrenic ʻelua. Arch Gen Psychiatry 1973; 28: 843-846. Nānā kiʻi ʻole.
55. ʻO Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, EH, a me Marsden, CD Clinical, biochemical, a me nā hiʻohiʻona physiological e hoʻomaopopo ana i ka myoclonus e pane i ka 5-hydroxytr Egyptophan, tryptophan me kahi monoamine oxidase mea kāohi, and clonazepam. ʻO Brain 1977; 100: 455-487. Nānā kiʻi ʻole.
56. Van Woert, M. H., Rosenbaum, D., Howieson, J., a me Bowers, M. B., Jr. Lohi lōʻihi o ka myoclonus a me nā maʻi neurologic ʻē aʻe me L-5- hydroxytr Egyptophan a me carbidopa. N Engl J Med 1-13-1977; 296: 70-75. Nānā kiʻi ʻole.
57. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS. L-5HTP i ke kūpikipiki kū ʻole i nā mea hōʻoki hou. ʻO kahi noi hoʻohālikelike hāmama me tranylcypromine. Br J Psychiatry 1985; 147: 16-22. Nānā kiʻi ʻole.
58. ʻO De Benedittis G, ʻo Massei R. Serotonin i mua o ka maʻi poʻo hina mua. ʻO kahi hoʻopaʻa pālua makapō makapō me L-5-hydroxytr Egyptophan vs. placebo. ʻO J Neurosurg Sci 1985; 29: 239-48. Nānā kiʻi ʻole.
59. ʻO Titus F, Dávalos A, Alom J, Codina A. 5-Hydroxytr Egyptophan me methysergide i ka prophylaxis o ka migraine. Hoʻokolokolo hoʻokolohua kaulike ʻia. Eur Neurol 1986; 25: 327-9. Nānā kiʻi ʻole.
60. ʻO Santucci M, Cortelli P, Rossi PG, Baruzzi A, Sacquegna T. L-5-hydroxytr Egyptophan me kahi placebo i ka migraine prophylaxis ʻōpio: he noi crossover makapō makapō. Cephalalgia 1986; 6: 155-7. Nānā kiʻi ʻole.
61. ʻO Irwin, M. R., Marder, S. R., Fuentenebro, F., a me Yuwiler, A. L-5-hydroxytr Egyptophan hoʻonāukiuki i nā hōʻailona psychotic maikaʻi i hoʻokomo ʻia e D-amphetamine. ʻO Psychiatry Res. 1987; 22: 283-289. Nānā kiʻi ʻole.
62. Angst J, Woggon B, Schoepf J. Ka mālama ʻana i ke kaumaha me L-5-hydroxytr Egyptophan versus imipramine. Nā hualoaʻa o ʻelua wehe a hoʻokahi aʻo ʻana makapō makapō. Arch Psychiatr Nervenkr 1977; 224: 175-86. Nānā kiʻi ʻole.
63. Kahn RS, Westenberg HG, Verhoeven WM, et al. Ka hopena o kahi preconoror serotonin a lawe i ka mea kāohi i nā maʻi hopohopo; ka hoʻohālikelike makapō-pālua o 5-hydroxytr Egyptophan, clomipramine a me placebo. Int Clin Psychopharmacol 1987; 21: 33-45. Nānā kiʻi ʻole.
64. ʻO De Giorgis G, Miletto R, Iannuccelli M, Camuffo M, Scerni S. Headache i ka hui pū ʻana me nā maʻi hiamoe o nā keiki: kahi loiloi psychodiagnostic a me ka hoʻokele hoʻokolohua hoʻokolohua - L-5-HTP versus placebo. Nā lāʻau lapaʻau Exp Clin Res 1987; 13: 425-33. Nānā kiʻi ʻole.
65. Zmilacher, K., Battegay, R., a me Gastpar, M. L-5-hydroxytr Egyptophan wale nō a me ka hui pū ʻana me ka mea hoʻopuni decarboxylase peripheral i ka mālama ʻana i ke kaumaha. Neuropsychobiology 1988; 20: 28-35. Nānā kiʻi ʻole.
66. Nolen, W. A., van de Putte, J. J., Dijken, W. A., Kamp, J. S., Blansjaar, B. A., Kramer, H. J., a me Haffmans, J. Hoʻolālā hoʻolālā i ke kaumaha. II. ʻO nā mea kāohi MAO i ke kaumaha e kūpaʻa i nā antidepressants cyclic: ʻelua mau noiʻi crossover i kāohi ʻia me tranylcypromine me L-5-hydroxytr Egyptophan a me nomifensine. ʻO Acta Psychiatr. Manaʻo 1988; 78: 676-683. Nānā kiʻi ʻole.
67. Kaneko M, Kumashiro H, Takahashi Y, Hoshino Y. L-5HTP lapaʻau a me ka pae 5-HT serum ma hope o ka hoʻouka ʻana o L-5-HTP i nā mea maʻi kaumaha. Neuropsychobiology 1979; 5: 232-40. Nānā kiʻi ʻole.
68. Rousseau JJ. Nā hopena o kahi levo-5-hydroxytr Egyptophan-dihydroergocristine hui pū ʻia me ke kaumaha a me ka hana neuropsychic: kahi hoʻokolohua hoʻokolohua hoʻokolohua hoʻokolohua lua-makapō i nā maʻi ʻelemakule. ʻO Clin Ther 1987; 9: 267-72. Nānā kiʻi ʻole.
69. Anders, T. F., Cann, H. M., Ciaranello, R. D., Barchas, J. D., a me Berger, P. A. ʻO nā mea i ʻike hou ʻia e pili ana i ka hoʻohana ʻana o 5-hydroxytr Egyptophan i kahi keiki me ka maʻi Lesch-Nyhan. Neuropadiatrie. 1978; 9: 157-166. Nānā kiʻi ʻole.
70. Ceci F, Cangiano C, Cairella M, et al. Nā hopena o ka hoʻoponopono 5-hydroxytr Egyptophan waha e pili ana i ka hana hānai ʻana i nā kumuhana wahine makua makua. ʻO J Neural Transm 1989; 76: 109-17. Nānā kiʻi ʻole.
71. Jangid P, Malik P, Singh P, Sharma M, Gulia AK. Ke aʻo hoʻohālikelike o ka pono o l-5-hydroxytr Egyptophan a me fluoxetine i nā mea maʻi e hōʻike nei me ka pae depressive mua. ʻO Asian J Psychiatr 2013; 6: 29-34. Nānā kiʻi ʻole.
72. Zarcone, V. P., Jr. a me Hoddes, E. Nā hopena o 5-hydroxytr Egyptophan ma ka ʻāpana o ka hiamoe Rem i nā mea ʻona ʻona. ʻO Am J Psychiatry 1975; 132: 74-76. Nānā kiʻi ʻole.
73. ʻO Opladen, T., Hoffmann, G. F., a me Blau, N. ʻO kahi ana honua no nā mea maʻi me nā hemahema tetrahydrobiopterin e hōʻike nei me hyperphenylalaninaemia. ʻO J Inherit. Metab Dis 2012; 35: 963-973. Nānā kiʻi ʻole.
74. Baraldi, S., Hepgul, N., Mondelli, V., a me Pariante, C. M. ʻO ka hoʻomaʻamaʻa simptomatik o ke kaumaha i loko o ka maʻi interferon-alpha i loko o ka hepatitis C: kahi loiloi ʻōnaehana. ʻO J Clin Psychopharmacol. 2012; 32: 531-543. Nānā kiʻi ʻole.
75. Pan, L., McKain, BW, Madan-Khetarpal, S., Mcguire, M., Diler, RS, Perel, JM, Vockley, J., a me Brent, DA GTP-cyclohydrolase deficit pane i sapropterin a me 5-HTP supplementation : ke kōkua o ke kaumaha-refrakst depression a me ke ʻano suicidal. Nānā BMJ.Rep. 2011; 2011 Nānā abstract.
76. Friedman, J., Roze, E., Abdenur, JE, Chang, R., Gasperini, S., Saletti, V., Wali, GM, Eiroa, H., Neville, B., Felice, A., Parascandalo, R., Zafeiriou, DI, Arrabal-Fernandez, L., Dill, P., Eichler, FS, Echenne, B., Gutierrez-Solana, LG, Hoffmann, GF, Hyland, K., Kusmierska, K., Tijssen, MA, Lutz, T., Mazzuca, M., Penzien, J., Poll-The BT, Sykut-Cegielska, J., Szymanska, K., Thony, B., a me Blau, N. Sepiapterin hōʻemi hoʻoliʻiliʻi: kahi mālama mimic o ka maʻi lolo. Ann Neurol. 2012; 71: 520-530. Nānā kiʻi ʻole.
77. ʻO Jukic T, Rojc B, Boben-Bardutzky D, Hafner M, Ihan A. Ka hoʻohana ʻana i kahi meaʻai me D-phenylalanine, L-glutamine a me L-5-hydroxytriptophan i ka hoʻopau ʻana i nā hōʻailona haʻalele i ka waiʻona. Coll Antropol 2011; 35: 1225-30. Nānā kiʻi ʻole.
78. ʻO Sarris, ʻo J. Clinical depression: kahi hōʻike hōʻike e pili ana i ka hoʻopili ʻia ʻana o ka lāʻau lapaʻau. ʻO Altern .her. ʻO Med Med. 2011; 17: 26-37. Nānā kiʻi ʻole.
79. ʻO Dill, P., Wagner, M., Somerville, A., Thony, B., Blau, N., a me Weber, P. Neurology kamaliʻi: paʻakikī ʻo paroxysmal, nānā i luna, a me hyponia: nā hiʻohiʻona o ka hemahema o ka sepiapterin reductase. Neurology 1-31-2012; 78: e29-e32. Nānā kiʻi ʻole.
80. Horvath, GA, Selby, K., Poskitt, K., Hyland, K., Waters, PJ, Coulter-Mackie, M., a me Stockler-Ipsiroglu, SG Hemiplegic migraine, ka hopu ʻana, nā spares paraparesis holomua, nā maʻi maʻi, a me ke koma i nā kaikaina me ka serotonin ʻōnaehana haʻahaʻa. Cephalalgia 2011; 31: 1580-1586. Nānā kiʻi ʻole.
81. Morrison, K. E. ʻO ke kaʻina genome āpau e hoʻomaopopo i ka mālama ʻana: hana ka lāʻau pilikino i kahi ʻē aʻe i mua. ʻO Clin Chem 2011; 57: 1638-1640. Nānā kiʻi ʻole.
82. Bainbridge, MN, Wiszniewski, W., Murdock, DR, Friedman, J., Gonzaga-Jauregui, C., Newsham, I., Reid, JG, Fink, JK, Morgan, MB, Gingras, MC, Muzny, DM, Hoang, LD, Yousaf, S., Lupski, JR, a me Gibbs, RA Ke kaʻina genome āpau no ka hoʻokele maikaʻi ʻana o ka mea maʻi. Unuhi ʻo Sci. Med 6-15-2011; 3: 87re3. Nānā kiʻi ʻole.
83. den Boer JA, Westenberg HG. Nā hopena Behavioural, neuroendocrine, a me nā hopena biochemical o 5-hydroxytr Egyptophan lawelawe i ka maʻi panic. ʻO Psychiatry Res 1990; 31: 267-78. Nānā kiʻi ʻole.
84. Adamsen, D., Meili, D., Blau, N., Thony, B., a me Ramaekers, V. Autism e pili ana me ka 5-hydroxyindolacetic acid haʻahaʻa ma CSF a me ka genter heterozygous SLC6A4 Gly56Ala a me nā mea hoʻolaha hoʻolaha 5-HTTLPR L / L . Mol. Genet. Metab 2011; 102: 368-373. Nānā kiʻi ʻole.
85. Cross, D. R., Kellermann, G., McKenzie, L. B., Purvis, K. B., Hill, G. J., a me Huisman, H. A randomized target amino acid therapy with behaviourally at-risk adopter. ʻO Dev Ke olakino mālama keiki. 2011; 37: 671-678. Nānā kiʻi ʻole.
86. ʻO Gendle, M. H. a me Golding, A. C. Hoʻokele waha o 5-hydroxytr Egyptophan (5-HTP) hoʻopilikia i ka hoʻoholo ʻana ma lalo o ke ʻano kānalua akā ʻaʻole ma lalo o ka makaʻu: nā hōʻike mai ka Iowa Gambling Task. Hum Psychopharmacol. 2010; 25: 491-499. Nānā kiʻi ʻole.
87. ʻO Iovieno, N., Dalton, E. D., Fava, M., a me Mischoulon, D. Nā antidepressants kūlohelohe ʻelua: loiloi a me nā loiloi. J Pili. Disord. 2011; 130: 343-357. Nānā kiʻi ʻole.
88. Leu-Semenescu, S., Arnulf, I., Decaix, C., Moussa, F., Clot, F., Boniol, C., Touitou, Y., Levy, R., Vidailhet, M., a me Roze, E. Nā hiamoe a me nā hopena hopena o kahi genetically induced loss of serotonin. Hiamoe 3-1-2010; 33: 307-314. Nānā kiʻi ʻole.
89. Freedman RR. ʻO ka mālama ʻana i nā uila wela menopausal me 5-hydroxytr Egyptophan. Maturitas 2010; 65: 383-5. Nānā kiʻi ʻole.
90. Nā pule hebedoma, B. S. Formulated o nā mea hoʻopihapihaʻai a me nā mea kanu lāʻau no ka hoʻomaha a me ka hana anxiolytic: Relarian. ʻO Med Sci Monit. 2009; 15: RA256-RA262. Nānā kiʻi ʻole.
91. Rondanelli M, Klersy C, Iadarola P, et al. ʻO ka māʻona a me ka amino-acid profile i nā wahine kaona kaupaona ma hope o kahi hoʻomaʻamaʻa hou e hoʻohana ana i kahi mea kanu kūlohelohe i ka unuhi sublingual. Int J Obes (Lond) 2009; 33: 1174-1182. Nānā kiʻi ʻole.
92. Maissen CP, Ludin HP. [Hoʻohālikelike i ka hopena o 5-hydroxytr Egyptophan a me propranolol i ka lawelawe waena o ka migraine]. ʻO Schweiz Med Wochenschr 1991; 121: 1585-90. Nānā kiʻi ʻole.
93. Shell W, Bullias D, Charuvastra E, et al. ʻO ka hoʻāʻo ʻana, kahi placebo-kāohi hoʻokolohua o kahi amino acid hoʻomākaukau i ka manawa a me ka maikaʻi o ka hiamoe. 'Am J Ther 2010; 17: 133-9. Nānā kiʻi ʻole.
94. Trujillo-Martin, M. M., Serrano-Aguilar, P., Monton-Alvarez, F., a me Carrillo-Fumero, R. Ka hopena a me ka palekana o nā mālama no nā ataxias degenerative: kahi ʻōnaehana loiloi. ʻO Mov Disord. 6-15-2009; 24: 1111-1124. Nānā kiʻi ʻole.
95. Rothman, R. B. Hoʻomaʻamaʻa i ka momona me ka "hoʻohui" ʻo ka lāʻau lapaʻau. ʻO Am J Ther 2010; 17: 596-603. Nānā kiʻi ʻole.
96. Chae, HS, Kang, OH, Choi, JG, Oh, YC, Lee, YS, Jang, HJ, Kim, JH, Park, H., Jung, KY, Sohn, DH, a me Kwon, DY 5-hydroxytr Egyptophan e hana ma ʻo ka mitogen-activated protein kinase extracellular-signal regulated protein kinase pathway e hoʻololi i ka cyclooxygenase-2 a me ka inducible nitric oxide synthase expression i nā RAW 264.7 pūnaewele. Biol Pharm Bull 2009; 32: 553-557. Nānā kiʻi ʻole.
97. ʻO Hendricks, E. J., Rothman, R. B., a me Greenway, F. L. Pehea e hoʻohana ai nā kauka lapaʻau ʻoi o ka momona i nā lāʻau e mālama i ka momona. Kaona. (Kālā. Puna) 2009; 17: 1730-1735. Nānā kiʻi ʻole.
98. Longo, N. Nā maʻi o ka metabolism biopterin. ʻO J Inherit. Metab Dis 2009; 32: 333-342. Nānā kiʻi ʻole.
99. ʻO Pons, R. The phenotypic spectrum of pediatric neurotransmitter maʻi a me ka pēpē parkinsonism. ʻO J Inherit. Metab Dis 2009; 32: 321-332. Nānā kiʻi ʻole.
100. Schaefer, M., Winterer, J., Sarkar, R., Uebelhack, R., Franke, L., Heinz, A., a me Friebe, A. ʻEkolu mau hihia o ka tryptophan add-on a monotherapy o ka hepatitis C a me IFNalpha -e hoʻopili i nā maʻi maʻi. Nā Psychosomatics 2008; 49: 442-446. Nānā kiʻi ʻole.
101. ʻO Jacobsen, JP, Nielsen, EO, Hummel, R., Redrobe, JP, Mirza, N., a me Weikop, P. Ka noʻonoʻo ʻole o nā ʻiole NMRI i nā mea hōʻoki hou i nā serotonin e koho ʻia i ka hoʻāʻo ʻana o ka huelo e hiki ke hoʻohuli ʻia e ka hana pū ʻana me 5. -hydroxytr Egyptophan. Psychopharmacology (Berl) 2008; 199: 137-150. Nānā kiʻi ʻole.
102. Liu, K. M., Liu, T. T., Lee, N. C., Cheng, L. Y., Hsiao, K. J., a me Niu, D. M. ʻO ka ukali wā lōʻihi o nā mea maʻi Kina Taiwanese i mālama mua ʻia no 6-pyruvoyl-tetrahydropterin synthase deficit. Arch Neurol. 2008; 65: 387-392. Nānā kiʻi ʻole.
103. Horvath, GA, Stockler-Ipsiroglu, SG, Salvarinova-Zivkovic, R., Lillquist, YP, Connolly, M., Hyland, K., Blau, N., Rupar, T., a me nā wai, PJ Autosomal recessive GTP cyclohydrolase I ka nele me ka ʻole o hyperphenylalaninemia: hōʻike o ka hoʻomau phenotypic ma waena o nā mana nui a me nā recessive. Mol. Genet. Metab 2008; 94: 127-131. Nānā kiʻi ʻole.
104. ʻApōpō, J. D., Vikraman, S., Imeri, L., a me Opp, M. R. Nā hopena o ka hoʻōla serotonergic e 5-hydroxytr Egyptophan i ka hiamoe a me ka mahana o ke kino o C57BL / 6J a me nāʻiole interleukin-6-hemahema ka mahele a me ka manawa e pili ana. Hiamoe 1-1-2008; 31: 21-33. Nānā kiʻi ʻole.
105. Meolie, AL, Rosen, C., Kristo, D., Kohrman, M., Gooneratne, N., Aguillard, RN, Fayle, R., Troell, R., Townsend, D., Claman, D., Hoban, T., a me Mahowald, M. Lapaʻau lāʻau ʻole no ka hiamoe ʻole: kahi loiloi o nā huahana me nā hōʻike palena palena. J Clin. Hiamoe Med 4-15-2005; 1: 173-187. Nānā kiʻi ʻole.
106. Cangiano C, Ceci F, Cairella M, et al. Nā hopena o 5-hydroxytr Egyptophan i ka ʻai ʻana i ka lawena a me ka mālama ʻana i nā kuhikuhi papaʻai i nā kumuhana makua makua. Adv Exp Med Biol 1991; 294: 591-3. Nānā kiʻi ʻole.
107. Petre-Quadens, O. lāua ʻo De Lee, C. 5-Hydroxytr Egyptophan a hiamoe ma Down's syndrome. ʻO J Neurol Sci 1975; 26: 443-453. Nānā kiʻi ʻole.
108. Lesch, K. P., Hoh, A., Disselkamp-Tietze, J., Wiesmann, M., Osterheider, M., a me Schulte, H. M. 5-Hydroxytr Egyptamine1A pane pane i ka mea loaʻa i ka maʻi obsessive-compulsive. Hoʻohālikelike o nā mea maʻi a me nā kaohi. ʻO Arch Gen Psychiatry 1991; 48: 540-547. Nānā kiʻi ʻole.
109. ʻO Halladay, AK, Wagner, GC, Sekowski, A., Rothman, RB, Baumann, MH, a me Fisher, H. Alterations i ka inu waiʻona, ka hopu ʻana i ka hopu ʻana, a me ka lawe ʻana o monoamine i nāʻiole i mālama ʻia me phentermine a me 5-hydroxy-L-tryptophan . Synaps 2006; 59: 277-289. Nānā kiʻi ʻole.
110. Curcio, J. J., Kim, L. S., Wollner, D., a me Pockaj, B. A. ʻO ka hiki o 5-hydryoxytr Egyptophan no ka hoʻoliʻiliʻi wela wela: kahi kuhiakau. Altern Med Rev 2005; 10: 216-221. Nānā kiʻi ʻole.
111. ʻO Victor, S. a me Ryan, ʻo S. W. Nā lāʻau no ka pale ʻana i ka huhū o ka migraine i nā keiki. ʻO Cochrane Database.Syst.Rev 2003;: CD002761. Nānā kiʻi ʻole.
112. ʻO George DT, Lindquist T, Rawlings RR, et al. Mālama ʻo Pharmacologic i ka pale i nā mea maʻi me ka waiʻona: ʻaʻohe hopena o 5-hydroxytr Egyptophan a i ʻole levodopa. ʻO Clin Pharmacol Ther 1992; 52: 553-60. Nānā kiʻi ʻole.
113. Shaw, K., Turner, J., a me Del Mar, C. Tryptophan a me 5-hydroxytr Egyptophan no ke kaumaha. ʻO Cochrane Pūnaewele. Syst Rev 2002;: CD003198. Nānā kiʻi ʻole.
114. Ciaranello, R. D., Anders, T. F., Barchas, J. D., Berger, P. A., a me Cann, H. M. Ka hoʻohana ʻana o 5-hydroxytr Egyptophan i kahi keiki me ka maʻi Lesch-Nyhan. Keiki Psychiatry Hum Hum 1976; 7: 127-133. Nānā kiʻi ʻole.
115. Anderson, L. T., Herrmann, L., a me Dancis, J. Ka hopena o L-5-hydroxytr Egyptophan i ka pilikino ponoʻī i ka maʻi ʻo Lesch-Nyhan: kahi hōʻike maikaʻi ʻole. Neuropadiatrie. 1976; 7: 439-442. Nānā kiʻi ʻole.
116. ʻO Growdon, J. H., Young, R. R., a me Shahani, B. T. L-5-hydroxytr Egyptophan i ka mālama ʻana i kekahi mau syndrome ʻokoʻa kahi i kaulana ai ka myoclonus. ʻO Neurology 1976; 26: 1135-1140. Nānā kiʻi ʻole.
117. ʻO Takahashi S, Kondo H, Kato N. Ka hopena o l-5-hydroxytr Egyptophan ma ka lolo monoamine metabolism a me ka loiloi ʻana i kāna hopena maʻi i nā mea maʻi kaumaha. ʻO J Psychiatr Res 1975; 12: 177-87. Nānā kiʻi ʻole.
118. ʻO Preshaw RM, Leavitt D, Hoag G. ʻO ke kākoʻo papaʻai 5-hydroxytr Egyptophan a me ka urinary 5-hydroxyindole acetic acid. CMAJ 2008; 178: 993. Nānā kiʻi ʻole.
119. ʻO Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytr Egyptophan: kahi loiloi i kona pono antidepressant a me nā hopena maikaʻi ʻole. J Clin Psychopharmacol 1987; 7: 127-37 .. Nānā i ka abstract.
120. Shaw K, Turner J, Del Mar C. Tryptophan a me 5-hydroxytr Egyptophan no ke kaumaha. ʻO Cochrane Database Syst Rev 2002;: CD003198. Nānā kiʻi ʻole.
121. ʻO Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Ke aʻo pālua makapō o 5-hydroxytr Egyptophan me kahi placebo i ka mālama ʻana i ka maʻi fibromyalgia mua. ʻO J Int Med Res 1990; 18: 201-9. Nānā kiʻi ʻole.
122. Johnson KL, Klarskov K, Benson LM, et al. Ke kūʻana o ka piko X a me nā mea e pili ana: ʻo ka poke i hōʻike ʻia i ka hihia e pili ana iā 5-hydroxy-L-tryptophan e pili ana me ka eosinophilia-myalgia syndrome. ʻO J Rheumatol 1999; 26: 2714-7. Nānā kiʻi ʻole.
123. Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction a me ka hahau ʻana ma hope o ka hoʻohana ʻana i nā lāʻau serotonergic. ʻO Neurology 2002; 58: 130-3. Nānā kiʻi ʻole.
124. U. S. ʻAi a me nā lāʻau hoʻomalu lāʻau, Center no ka palekana o ka meaʻai a me ka meaʻai pono e noi ʻia, Ke keʻena o nā huahana mea pono, ka lepili ʻana, a me nā mea hoʻohui meaʻai. Ka Pepa ʻIke Ma L-Tryptophan a me 5-hydroxy-L-tryptophan, Pepeluali 2001.
125. Nardini M, De Stefano R, Iannuccelli M, et al. ʻO ka mālama ʻana i ke kaumaha me L-5-hydroxytr Egyptophan i hui pū ʻia me ka chlorimipramine, kahi noiʻi makapō makapō. Int J Clin Pharmacol Res 1983; 3: 239-50. Nānā kiʻi ʻole.
126. ʻO Ribeiro CA. L-5-Hydroxytr Egyptophan i loko o ka prophylaxis o ka maʻi ahulau kūpilikiʻi mau loa: kahi makapō makapō makapō, hoʻokolohua ʻole ʻia, placebo-kāohi ʻia. Headache 2000; 40: 451-6. Nānā kiʻi ʻole.
127. ʻO Poldinger W, Calanchini B, Schwarz W. He ʻano hana i ke kaumaha: nele i ka serotonin ma ke ʻano he syndrome target i ka hoʻohālikelike ʻana o 5-hydroxytr Egyptophan a me fluvoxamine. Psychopathology 1991; 24: 53-81. Nānā kiʻi ʻole.
128. Sternberg EM, Van Woert MH, Young SN, et al. Ke hoʻomohala ʻana i kahi maʻi e like me ka scleroderma i ka wā o ka therapy me L-5-hydroxytr Egyptophan a me carbidopa. N Engl J Med 1980; 303: 782-7. Nānā kiʻi ʻole.
129. ʻO ka US Food and Drug Administration. Hōʻoia nā impurities i ka papaʻai papa 5-hydroxy-L-tryptophan. Pepa kamaʻilio a FDA, ʻAukake 31, 1998; T98-48.
130. Meyer JS, Welch KM, Deshmukh VD, et al. ʻO Neurotransmitter precursor amino acid i ka mālama ʻana i ka dementia multi-infarct a me ka maʻi ʻo Alzheimer. ʻO J Amer Geriat Soc 1977; 25: 289-98. Nānā kiʻi ʻole.
131. ʻO Trouillas P, Brudon F, Adeleine P. Hoʻonui o ka cerebellar ataxia me ka levorotatory form o 5-hydroxytr Egyptophan: kahi papa makapō makapō me ka nui o ka hana ʻana i ka ʻikepili. Arch Neurol 1988; 45: 1217-22. Nānā kiʻi ʻole.
132. Kahn RS, Westenberg HG. L-5-hydroxytr Egyptophan i ka mālama ʻana i nā maʻi pīhoihoi. ʻO J Affect Disord 1985; 8: 197-200. Nānā kiʻi ʻole.
133. Cangiano C, Ceci F, Cancino A, et al. ʻO ka hana ʻana i ka lawaiʻa a me ke kūpaʻa i nā kuhikuhi papaʻai i nā mea makua makua momona i mālama ʻia me 5-hydroxytr Egyptophan. ʻO Am J Clin Nutr 1992; 56: 863-7. Nānā kiʻi ʻole.
134. ʻO Sarzi Puttini P, Caruso I. Syndrome fibromyalgia mua a me 5-hydroxy-L-tryptophan: kahi 90 mau lā e wehe ai i kahi noiʻi. ʻO J Int Med Res 1992; 20: 182-9. Nānā kiʻi ʻole.
135. Nakajima T, Kudo Y, Kaneko Z. ʻO ka loiloi loiloi o 5-hydroxy-L-tryptophan ma ke ʻano he lāʻau antidepressant. ʻO Folia Psychiatr Neurol Jpn 1978; 32: 223-30. Nānā kiʻi ʻole.
136. ʻO Michelson D, ʻAoʻao SW, Casey R, et al. ʻO kahi maʻi eosinophilia-myalgia e pili ana i ka maʻi e pili ana i ka hōʻike ʻana iā L-5-hydroxytr Egyptophan. ʻO J Rheumatol 1994; 21: 2261-5. Nānā kiʻi ʻole.
137. Manu Manu TC. 5-Hydroxytr Egyptophan: He mea hoʻomaikaʻi Serotonin Precursor. Altern Med Rev 1998; 3: 271-80. Nānā kiʻi ʻole.

Nānā hope - 12/29/2020